MRNA

Companies
NASDAQ
Moderna Inc.
Health Care
Price Chart
Overview

About MRNA

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Market Cap
$57.9B
Volume
316.5M
Avg. Volume
256.4M
P/E Ratio
-2.8574715
Dividend Yield
0.00%
Employees
5.3K

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.83
Moderate Correlation
Volatility
High (0.70)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for MRNA.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, MRNA shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$57.9B
Volume316.5M
P/E Ratio-2.86
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 1, 2025

PortfolioPilot Analysis

Get AI-powered insights on how MRNA fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025